Nipro Corporation

Matsushita Electric Industrial Co., Ltd.

Panasonic Corporation

Nissho Corporation

Toshiya Kai

Makoto Sato

Naohisa Katayama

Masaki Otagiri

Kazutaka Fujiki

Kazuyuki Yamamoto

Yoshinori Kida

Shinji Takeoka

Eishun Tsuchida

Yoshihisa Hama

Teruyuki Komatsu

Minoru Sano

Masakazu Mameta

Ippei Fukutomi

Junichi Yokoe

Keisuke Nakajo

Kenichi Kawaguchi

Hiroaki Kato

Takeshi Nizuka

Hiromi Sakai

Hidenori Nanki

Shiro Yoshioka

Kazumi Yamada

Yohei Hoashi

Keisuke Nakajou

Keitaro So

Ippei Hukutomi

Yuko Azuma

Hideaki Murata

Shinichiro Fukai

Shiho Sakuragi

Jun-Ichi Yokoe

Noami Ohmichi

Nobuyuki Hori

Yuko Suka

An oral solid preparation including a base compound and a powdery or granular additive colored with a colorant and a method of manufacturing an oral solid preparation including the steps of: coloring an additive with a colorant, mixing the resultant additive with a base compound, and tableting the mixture.

Oral solid preparation and method of manufacturing the same

Glycosylated albumin as a drug carrier for a DDS targeting the liver (particularly kupffer's cell) can be provided by mutating a DNA encoding albumin to encode a mutant albumin containing a partial amino acid sequence permitting glycosylation modification by eukaryotic cell, preferably a consensus sequence of N-linked sugar chain, introducing an expression vector containing the mutant DNA into a host eukaryotic cell, preferably a host cell permitting addition of a high-mannose type sugar chain, culturing the obtained transformant, and recovering a glycosylated albumin protein from the obtained culture.

Sugar chain-containing albumin, production method thereof and use thereof

The present invention provides an S-nitroso group-containing albumin, comprising an S-nitroso group introduced to at least one lysine in the amino acid sequence for albumin. The S-nitro group has been introduced into a lysine in the S-nitroso group-containing albumin of the invention to allow more S-nitroso groups to be included in the albumin, thus ensuring more potent inhibition of cancer cells in NO groups.

S-nitroso group-containing albumin, method for production, and anticancer agent

A method of removing carbon monoxide from an oxygen carrier including setting a carbon monoxide bonded oxygen carrier solution across a separation membrane from an oxygen-dissolved solution; and exposing the setting part to the light and a method of removing carbon monoxide from an oxygen carrier including setting a carbon monoxide oxygen carrier solution across a hollow fiber separation membrane from an oxygen-dissolved solution; and exposing the setting part to light.

Method of removing carbon monoxide from an oxygen carrier and apparatus for removing carbon monoxide

An information processing apparatus comprising a secure information unit that is set to the state not requiring security in the case where the data is transferred from a user memory space to a general purpose register, and that is set to the state requiring security in the case where the data is transferred from a secure memory space to the general purpose register. An encryption key in the secure memory space is prevented from being stolen by prohibiting the data transfer to the user memory space from the general purpose register with the value of the secure information unit set to the state requiring security.

Information processing apparatus for accessing memory spaces including a user memory space and a secure memory space

A pharmaceutical composition containing an artificial oxygen carrier, which has high oxygen carrying efficiency; and has a required colloid osmotic pressure, an appropriate crystalloid osmotic pressure, pH, and electrolyte balance. The composition is prepared by appropriately adding at least one substance selected from the group consisting of a compound capable of providing a colloid osmotic pressure, an electrolyte, a saccharide, an amino acid, an antioxidant, a pH adjuster, and an isotonizing agent to a preparation including a liposome-encapsulated hemoglobin in which a hemoglobin is encapsulated in a liposome or to a preparation including a conjugate of a porphyrin-iron complex and albumin.

Pharmaceutical composition containing artificial oxygen carrier

This invention provides albumin preparations with safety and without any risk of side effects, which are free from viruses or contaminating proteins and can be stably stored over a long time while showing neither changes in appearance nor decrease in content. There are provided a stabilized albumin preparation produced by uniformly mixing a medium-chain fatty acid or a salt thereof and a sulfur-containing amino acid or a derivative thereof with an aqueous albumin solution (e.g., a buffer such as phosphate buffer which can be administered as pharmaceutical preparations, injection water, or a physiological saline) and dissolving them therein, and then processing the mixture solution into a formulation suitable for parenteral administration such as an intravenous fluid preparation or an injectable solution, and a stabilization method for an albumin preparation.

Stabilized albumin preparations

The present invention provides a method of producing a complex of albumin and a deoxy form metal complex having a porphyrin structure, which includes mixing albumin and a metal complex having a porphyrin structure under a gas atmosphere substantially free of carbon monoxide and oxygen, as a method of producing an artificial oxygen carrier containing a complex of albumin and a metal complex having a porphyrin structure, under a deoxidation (nitrogen, other inert gases) atmosphere without using carbon monoxide.

Artificial oxygen carrier and production method thereof

A protein produced by gene recombinant technology, including at least one domain selected from domains I, II, and III of serum albumin but having a different structure from that of native albumin; and a method of producing the protein. The protein has an enhanced functional activity or activities selected from among various functional activities or serum albumin including antibacterial activity, antioxidative effect, inflammation inhibitory effect, in vivo substance transporting action, and enzymatic activity.

Protein containing serum albumin domain

A solid preparation for dialysis for preparing a double preparation type sodium bicarbonate solid preparation for dialysis in which there is no fear that a sugar component is decomposed or colored, and which can maintain stability and is also excellent in content homogeneity and a process for producing the same. The solid preparation for dialysis is a mixture of a first composition composed of core particles including sodium chloride and a coating layer containing one or more electrolytes, a second composition composed of core particles including a sugar that is covered with a coating layer comprising the same sugar or a different sugar, and an acid.

Solid preparation for dialysis and process for producing the same

The present invention provides a plastic container containing albumin solution and a packaged plastic container containing an albumin solution. The plastic container containing an albumin solution having an albumin concentration of 1 to 500 mg/ml, has at least one inlet/outlet for a liquid, and has a water vapor permeability of 1.5 g/m /day&middot;1013.25 hPa or less when the vapor permeability is measured at a pressure of 1013.25 hPa per surface area of 1 m for 24 hours at a temperature of 25&deg; C. and at a relative humidity of 60%. The plastic container containing an albumin solution can be packaged with an outer packaging material to provide the packaged plastic container.

Plastic container containing albumin solution

A solid preparation for dialysis for preparing a double preparation type sodium bicarbonate solid preparation for dialysis in which there is no fear that a sugar is decomposed or colored, and which can maintain stability and also is excellent in content homogeneity and a process for producing the same. The solid preparation for dialysis is a mixture of a first composition composed of core particles including sodium chloride that are coated with a coating layer containing one or more electrolytes, a second composition composed of core particles including a sugar that are covered with a coating layer containing one or more electrolytes, and an acid.

A one-pack solid pharmaceutical composition for dialysate containing sodium bicarbonate which can prevent the reactions between sodium bicarbonate and acetic acid and between sodium bicarbonate and electrolytes, and is excellent in long term storage stability is provided. The solid pharmaceutical composition for dialysate containing sodium bicarbonate is a mixture of an agent A containing sodium chloride, calcium chloride, magnesium chloride, potassium chloride, sodium acetate and acetic acid and an agent B containing sodium bicarbonate coated with sodium acetate.

Solid pharmaceutical composition for dialysate containing sodium bicarbonate and a process for producing the same

To provide a plastic vessel containing an albumin preparation which completely restrains formation of thermally denatured albumin, a plastic molded member in a cylindrical shape is extruded in a molten state into opened dies, one end of which is closed in the dies, and a vessel is molded by blowing a compressed gas into the molded member in the dies or by bringing inner portions of the dies into a vacuum state. While the vessel is still disposed in the dies, an albumin preparation is introduced from an opening portion into an inner portion of the vessel and, therefore, the albumin preparation can be filled into the vessel in a sterilized state without being brought into contact with the atmosphere. Then, an opening portion of the vessel filled with the albumin preparation is hermetically sealed at an internal temperature of the opening portion of about 40 to 70&deg; C. Thus formation of thermally denatured albumin can be completely restrained.

Plastic vessel containing an albumin preparation

An E,PROM controller is provided for an emulation chip. An E,PROM is connected to a CPU via a memory interconnect bus. The E,PROM and the CPU are also connected to each other via a peripheral circuit interconnect bus independent of the memory interconnect bus. During emulation, the emulation chip is connected to an in-circuit emulator via an emulator interconnect bus, and the memory interconnect bus is disconnected. However, the E,PROM controller allows electrical communication through the peripheral circuit interconnect bus and thereby accesses the E,PROM as one of peripheral circuits. Accordingly, it is possible to check out whether or not a reprogramming program stored in the E,PROM is running normally.

Growing community of inventors

Osaka, Japan

Toshiya Kai